In 419 patients with P vivax malaria in Brazil, day-42 recurrence was similar with dihydroartemisinin-piperaquine vs chloroquine when primaquine started on day 0 (1.0% vs 2.0%), but lower when primaquine was delayed to day 42 (2.4% vs 27.3%; HR 0.08).
RCTn = 419 patients
Baía-da-Silva et al. Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial